reglab/statecodes huggingface dataset:
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-91 - Establishment; purpose.

26:2-91 Establishment; purpose.
2. The State Department of Health hereafter referred to as the department shall establish a program for the care and treatment of persons suffering from hemophilia, qualitative platelet disorders, and von Willebrand disease. This program shall assist persons who require continuing treatment with blood and blood derivatives to avoid crippling, extensive hospitalization and other effects associated with these critical chronic bleeding conditions, but who are unable to pay for the entire cost of such services on a continuing basis despite the existence of various types of hospital and medical insurance coverages, Medicare, Medicaid, and other government assistance programs, and private charitable assistance programs.
L.1972, c.124, s.2; amended 2019, c.259, s.2.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-92 - Powers and duties of department.

26:2-92 Powers and duties of department.
3. The department shall:
a. Develop standards for determining eligibility for care and treatment under this program;
b. Assist in the development and expansion of programs for the care and treatment of persons suffering from hemophilia, qualitative platelet disorders, and von Willebrand disease, including self-administration, prevention, and home care and other medical and dental procedures and techniques designed to provide maximum control over bleeding episodes typical of these conditions;
c. Extend financial assistance to persons suffering from hemophilia, qualitative platelet disorders, and von Willebrand disease in obtaining blood, blood derivatives, and concentrates, and other efficacious agents for use in hospital, medical, and dental facilities, and at home, or participate in the cost of blood processing to the extent that such support will facilitate the supplying of blood, blood derivatives, and concentrates and other efficacious agents to patients at an economical cost, thus increasing the effectiveness of the moneys appropriated to carry out the provisions of P.L.1972, c.124 (C.26:2-90 et seq.);
d. Institute and carry on educational programs among patients, physicians, dentists, hospitals, public health departments, and the public concerning hemophilia, qualitative platelet disorders, and von Willebrand disease, including dissemination of information and the conducting of educational programs concerning the methods of care and treatment of persons suffering from these conditions; and
e. Promulgate all rules and regulations necessary to effectuate the purposes of P.L.1972, c.124 (C.26:2-90 et seq.).
L.1972, c.124, s.3; amended 2019, c.259, s.3.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-94 - Public policy

26:2-94. Public policy
It is hereby declared to be the policy of the State that no child shall be denied access to any medical assistance which may prolong his or her life because of inability to pay the cost thereof. The Legislature hereby finds that there are cases where a child's illness has been diagnosed as terminal and all remedies and finances have been exhausted, and only by continued medical and financial assistance could the child's life be prolonged. It is, therefore, declared to be the policy of the State that, in such cases, the State shall provide assistance in the case of medical expenses.
L.1972, c. 193, s. 2, eff. Dec. 20, 1972.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-95 - Program of care and treatment; establishment

26:2-95. Program of care and treatment; establishment
The State Department of Health shall establish a program for the care and treatment of children suffering from terminal illnesses. This program shall assist children suffering from such illnesses who require lifesaving care and treatment therefor, but whose parents or guardian are unable to pay for such services on a continuing basis.
L.1972, c. 193, s. 3, eff. Dec. 20, 1972.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-96 - Definitions

26:2-96. Definitions
For the purposes of this act:
a. "Child" means any person under 21 years of age.
b. "Terminal illness" means an illness for which there is no known cure and which ultimately ends in death, and which has been certified as such by two physicians licensed to practice medicine and surgery.
c. "Department" means the State Department of Health.
d. "Commissioner" means the State Commissioner of Health.
L.1972, c. 193, s. 4, eff. Dec. 20, 1972.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-97 - Terminal illness advisory committee; members; term of office; meetings; compensation

26:2-97. Terminal illness advisory committee; members; term of office; meetings; compensation
The commissioner shall appoint a Terminal Illness Advisory Committee, hereafter referred to as the committee, to consult with the department in the administration of this act. The committee shall be composed of 11 persons representing hospitals and medical schools, voluntary agencies interested in terminal illness, local public health agencies, physicians licensed to practice medicine in all of its branches, and the general public. Each member shall hold office for a term of 4 years and until his successor is appointed and qualified, except that the terms of the members first taking office shall expire, as designated at the time of appointment, two at the end of the first year, three at the end of the second year, three at the end of the third year, and three at the end of the fourth year, after the date of appointment. Any person appointed to fill a vacancy occurring prior to the expiration of the term for which his predecessor was appointed shall be appointed for the remainder of such term. The committee shall meet as frequently as the secretary deems necessary, but not less than once each year. The committee members shall receive no compensation but shall be reimbursed for actual expenses incurred in carrying out their duties as members of this committee.
L.1972, c. 193, s. 5, eff. Dec. 20, 1972.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-98 - Powers and duties of department

26:2-98. Powers and duties of department
The department shall:
a. With the advice of the committee, develop standards for determining eligibility for care and treatment under this program.
b. Assist in the development and expansion of programs for the care and treatment of children suffering from terminal illnesses, including medical procedures and techniques which will have a lifesaving effect in the care and treatment of persons suffering from these diseases.
c. Assist in the development of programs for the prevention of terminal illnesses.
d. Extend financial assistance to children suffering from terminal illnesses in obtaining the medical, nursing, pharmaceutical, and technical services in caring for such diseases.
e. Promulgate rules and regulations necessary to effectuate the purposes of this act.
L.1972, c. 193, s. 6, eff. Dec. 20, 1972.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-99 - Right to refuse medical examination, diagnosis or treatment on religious grounds

26:2-99. Right to refuse medical examination, diagnosis or treatment on religious grounds
Nothing in this act shall be construed to compel any person to undergo any medical screening, examination, diagnosis, or treatment or to accept any other health care (other than for the purpose of discovering and preventing the spread of infection or contagious disease or for the purpose of protecting environmental health), if the child or his parent or guardian objects thereto on religious grounds.
L.1972, c. 193, s. 7, eff. Dec. 20, 1972.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-100 - Severability

26:2-100. Severability
If any clause, sentence, section, provision, or part of this act shall be adjudged to be unconstitutional or invalid for any reason by any court of competent jurisdiction, such judgment shall not invalidate, impair or affect the remainder of this act, which shall remain in full force and effect.
L.1972, c. 193, s. 8, eff. Dec. 20, 1972.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-103.1 - Findings, declarations relative to universal newborn hearing screening.

26:2-103.1 Findings, declarations relative to universal newborn hearing screening.
1. The Legislature finds and declares that:
Hearing loss occurs in newborns more frequently than any other health condition for which newborn screening is currently required. Moreover, early detection of hearing loss in a child and early intervention and treatment before six months of age has been demonstrated to be highly effective in facilitating a child's healthy development in a manner consistent with the child's age and cognitive ability. Eighty percent of a child's ability to learn speech, language and related cognitive skills is established by the time the child is 36 months of age, and hearing is vitally important to the healthy development of such language skills. Due to advances in medical technology, children of all ages can receive reliable and valid screening for hearing loss in a cost-effective manner. Appropriate screening and identification of newborns and infants with hearing loss will facilitate early intervention and treatment in the critical time period for language development, and may, therefore, serve the public purposes of promoting the healthy development of children and reducing public expenditures for health care and special education and related services.
Therefore, it is necessary for the Legislature to establish a universal newborn hearing screening program that will: a. provide early detection of hearing loss in newborn children at the hospital or birthing center or as soon after birth as possible; b. enable these children and their care givers to obtain needed multi-disciplinary evaluation, treatment, and intervention services at the earliest opportunity; and c. prevent or mitigate the developmental delays and academic failures associated with late identification of hearing loss.
L.2001,c.373,s.1.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-103.2 - Definitions relative to universal newborn hearing screening.

26:2-103.2 Definitions relative to universal newborn hearing screening.
2. As used in this act:
"Commissioner" means the Commissioner of Health.
"Department" means the Department of Health.
"Electrophysiologic screening measures" means the electrical result of the application of physiologic agents and includes, but is not limited to, the procedures currently known as Auditory Brainstem Response testing (ABR) and Otoacoustic Emissions testing (OAE) and any other procedure adopted by regulation by the commissioner.
"Hearing loss" means a hearing loss of 30dB or greater in the frequency region important for speech recognition and comprehension in one or both ears, which is approximately 500 through 4000 Hz., except that the commissioner may adopt a standard which establishes a less severe hearing loss, as appropriate.
"Newborn" means a child up to 28 days old.
"Parent" means a biological parent, stepparent, adoptive parent, legal guardian, or other legal custodian of a child.
L.2001, c.373, s.2; amended 2012, c.17, s.112.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-103.3 - Screening for hearing loss in all newborn children.

26:2-103.3 Screening for hearing loss in all newborn children.
3. a. The commissioner shall ensure that, effective January 1, 2002, all newborn children in the State shall be screened for hearing loss by an appropriate electrophysiologic screening measure.
b. Effective January 1, 2002, the department shall issue guidelines for the periodic monitoring of all infants between the age of 29 days and 36 months for delayed onset hearing loss.
c. Notwithstanding the provisions of subsection a. of this section to the contrary, no newborn child shall be screened for hearing loss if the parent of the newborn objects to such screening on the grounds that the screening conflicts with the parents' bona fide religious tenets or practices.
L.2001,c.373,s.3.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-103.4 - Hospital, birthing center to provide for newborn screening for hearing loss.

26:2-103.4 Hospital, birthing center to provide for newborn screening for hearing loss.
4. Every hospital that provides inpatient maternity services and every birthing center licensed in the State pursuant to P.L.1971, c.136 (C.26:2H-1 et seq.) shall be required to provide for newborn screening for hearing loss for all newborns born at the facility. The hospital or birthing center shall file a plan with the department, in a manner and on forms prescribed by the commissioner, detailing how the hospital or birthing center will implement the newborn hearing screening requirements established pursuant to this act. The plan shall include, at a minimum, the following:
a. the electrophysiologic screening measure to be performed;
b. the qualifications of the personnel designated to perform the electrophysiologic screening measure;
c. guidelines for the provision of follow-up services for newborns identified as having or being at risk of developing a hearing loss;
d. the educational services to be provided to the parents of newborns identified as having or being at risk for developing a hearing loss; and
e. the protocol to be followed to ensure the confidentiality of any patient identifying information furnished to the department for the purposes of the central registry established pursuant to this act.
L.2001,c.373,s.4.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-103.5 - Physician, midwife to advise parent of availability of newborn hearing screening.

26:2-103.5 Physician, midwife to advise parent of availability of newborn hearing screening.
5. In the case of a newborn born outside of a hospital or birthing center who is not transferred to a hospital or birthing center, the physician or midwife, licensed in this State pursuant to Title 45 of the Revised Statutes, caring for the newborn shall advise the parent or guardian of the newborn of the availability of newborn hearing screening pursuant to this act, and shall take such actions as may facilitate the provision of such screening to the newborn in accordance with the provisions of this act.
L.2001,c.373,s.5.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-103.6 - Central registry of newborns at risk of hearing loss.

26:2-103.6 Central registry of newborns at risk of hearing loss.
6. a. The commissioner shall establish a central registry of newborns identified as having or being at risk of developing a hearing loss. The information in the central registry shall be used for the purposes of compiling statistical information and providing follow-up counseling, intervention and educational services to the parents of the newborns listed in the registry.
b. A hospital, birthing center or health care professional who performs testing required by this act shall report the results of such testing when a hearing loss is indicated to the department in a manner and on forms prescribed by the commissioner.
L.2001,c.373,s.6.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-103.7 - Screening, monitoring covered service.

26:2-103.7 Screening, monitoring covered service.
7. The Commissioner of Human Services shall ensure that the newborn hearing screening and periodic monitoring of infants for delayed onset hearing loss required pursuant to this act is a covered service under the State Medicaid program established pursuant to P.L.1968, c. 413 (C.30:4D-1 et seq.),the "Children's Health Care Coverage Program"established pursuant to P.L.1997, c.272 (C.30:4I-1 et seq.), and the "FamilyCare Health Coverage Program" established pursuant to P.L.2000, c.71 (C.30:4J-1 et seq.).
L.2001,c.373,s.7.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-103.8 - Hearing Evaluation Council.

26:2-103.8 Hearing Evaluation Council.
8. The commissioner shall establish a Hearing Evaluation Council to provide on-going advice to the department on implementation of this act. The council shall be composed of not less than seven persons appointed by the commissioner who include: a board certified pediatrician, a board certified otolaryngologist, an audiologist with certified clinical competence, a person who is profoundly deaf, a person who is hearing impaired, a hearing person of parents who are deaf, and a citizen of the State who is interested in the concerns and welfare of the deaf.
Each member shall hold office for a term of two years and until each member's successor is appointed and qualified. Any person appointed to fill a vacancy occurring prior to the expiration of the term for which the person's predecessor was appointed shall be appointed for the remainder of such term.
The council shall meet as frequently as the commissioner deems necessary, but not less than once each year. Council members shall receive no compensation but shall be reimbursed for actual expenses incurred in carrying out their duties as members of this council.
L.2001,c.373,s.8.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-103.9 - Rules, regulations.

26:2-103.9 Rules, regulations.
9. The commissioner, pursuant to the "Administrative Procedure Act," P.L.1968, c.410 (C.52:14B-1 et seq.), shall adopt rules and regulations necessary to implement the provisions of this act.
L.2001,c.373,s.9.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-104 - Legislative findings and declaration

26:2-104. Legislative findings and declaration
The Legislature hereby finds and declares:
a. That New Jersey is currently suffering from the highest overall mortality rates for cancer in the Nation;
b. That certain forms of cancer are now believed to be attributable to environmental factors which, if controlled, can significantly reduce cancer incidence in this State;
c. That more complete and more precise statistical data are necessary to determine the correlations between cancer incidence and possible environmental factors and to evaluate cancer treatment and prevention measures that are currently in progress; and,
d. That a cancer registry would thus provide a vital foundation for a concerted State effort to reduce the incidence of environmentally related cancer in this State.
L.1977, c. 266, s. 1.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-105 - Establishment, maintenance of State cancer registry.

26:2-105 Establishment, maintenance of State cancer registry.
2. The Department of Health shall establish and maintain an up-to-date registry which shall include a record of cases of cancer and specified cases of tumorous or precancerous disease that occur in New Jersey, and such information concerning these cases as it shall deem necessary and appropriate in order to conduct thorough and complete epidemiologic surveys of cancer and cancer-related diseases in this State and to apply appropriate preventive and control measures.
L.1977, c.266, s.2; amended 2001, c.99, s.1; 2012, c.17, s.113.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-107 - Confidentiality of reports.

26:2-107 Confidentiality of reports.
4. The reports made pursuant to this act are to be used only by the Department of Health and such other agencies as may be designated by the Commissioner of Health and shall not otherwise be divulged or made public so as to disclose the identity of any person to whom they relate; and to that end, such reports shall not be included under materials available to public inspection pursuant to P.L.1963, c.73 (C.47:1A-1 et seq.).
L.1977, c.266, s.4; amended 2001, c.99, s.3; 2012, c.17, s.115.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-108 - Immunity from liability for individuals, organizations providing information.

26:2-108 Immunity from liability for individuals, organizations providing information.
5. No individual or organization providing information to the Department of Health in accordance with this act shall be deemed to be, or held liable for, divulging confidential information.
L.1977, c.266, s.5; amended 2001, c.99, s.4; 2012, c.17, s.116.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-109 - Inapplicability of act to compel individual to submit to medical or health department examination or supervision

26:2-109. Inapplicability of act to compel individual to submit to medical or health department examination or supervision
Nothing in this act shall be construed to compel any individual to submit to medical or health department examination or supervision.
L.1977, c. 266, s. 6.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-110 - Findings, declarations relative to screening for disorders in newborn infants.

26:2-110 Findings, declarations relative to screening for disorders in newborn infants.
1. The Legislature finds and declares that:
a. Newborn screening is an essential public health activity that strives to screen every newborn infant for a variety of congenital disorders, which, if not detected and managed early, can result in significant morbidity, mortality, and disability. The State's newborn screening system shall be a coordinated and comprehensive effort to provide education, screening, follow-up, diagnosis, treatment and management, and program evaluation activities ;
b. Ongoing advances in technologies and treatment modalities make it possible to screen newborn infants for a wide array of biochemical disorders. It is imperative that the State adjust its Newborn Screening Program to incorporate these biochemical disorders to ensure that the program remains at the forefront of these advances; and
c. It is the intent of this act to protect the health and quality of life of newborn infants born in this State by enhancing the capacity to screen for congenital disorders and by providing: all newborn infants with screens for certain conditions and with appropriate referrals and early medical intervention when warranted; and newborn data collection is standardized, and conditions detected by newborn screening are tracked and monitored. Further, information on newborn screening and conditions for which a newborn can be screened should be readily accessible, current, and understandable to both health care providers and parents or guardians.
L.1977, c.321, s.1; amended 1981, c.357, s.2; 1988, c.24, s.2; 2019, c.296, s.1.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-110a - Newborn Screening Advisory Review Committee.

26:2-110a Newborn Screening Advisory Review Committee.
2. The Commissioner of Health shall establish a Newborn Screening Advisory Review Committee to annually review the disorders included in the Newborn Screening Program, screening technologies, treatment options, and educational and follow-up procedures. The committee shall include, but need not be limited to, medical, hospital, and public health professionals, scientific experts, and consumer representatives and advocates. The committee shall meet annually to review and revise the list of disorders recommended for inclusion in the Newborn Screening Program. The committee shall allow for public input in the course of conducting its review and issue recommendations to the commissioner on the improvement of the Newborn Screening Program.
L.2019, c.296, s.1.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-111.1 - Option of additional screening for disorders in infant required; cost.

26:2-111.1 Option of additional screening for disorders in infant required; cost.
1. a. A health care provider shall give an infant's parent or guardian the option of consenting to the performance of testing by qualified laboratories for disorders in infants for which testing is not required pursuant to P.L.1977, c.321 (C.26:2-110 et seq.), on a form and in a manner prescribed by the Commissioner of Health. The health care provider shall not be required to assume the cost of such testing.
As used in this section:
"Health care provider" means a health care professional licensed pursuant to Title 45 of the Revised Statutes or a health care facility licensed pursuant to Title 26 of the Revised Statutes that provides health care services to newborn infants.
"Qualified laboratory" means a clinical laboratory not operated by the Department of Health, which is certified by the Secretary of Health and Human Services pursuant to the federal "Clinical Laboratory Improvement Amendments of 1988," Pub.L.100-578 (42 U.S.C. s.263a) and reports its test results by using normal pediatric reference ranges.
b. (1) The Commissioner of Health shall prepare and make available electronically, on the Internet website of the Department of Health, information that explains the availability of testing performed by qualified laboratories for disorders in infants for which testing is not required pursuant to P.L.1977, c.321 (C.26:2-110 et seq.).
(2) A health care provider shall give an infant's parent or guardian a hard copy of the information prepared pursuant to paragraph (1) of this subsection and provide the parent or guardian with a reasonable opportunity to read the information when giving the parent or guardian the option of consenting to the performance of testing pursuant to subsection a. of this section.
L.2004, c.12, s.1; amended 2012, c.17, s.117.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-111.2 - HIV testing required for certain newborns.

26:2-111.2 HIV testing required for certain newborns.
4. a. The Commissioner of Health shall require each birthing facility in the State to administer to a newborn in its care a test for human immunodeficiency virus (HIV) if the HIV status of the mother of the newborn is unknown.
A newborn shall not be denied testing for HIV on the basis of the newborn's economic status.
b. The commissioner shall establish a comprehensive program for the follow-up testing of newborns who test positive for HIV pursuant to subsection a. of this section or whose mother is HIV-positive, which shall include, but not be limited to, procedures for the administration of HIV testing, counseling of the newborn's mother, tracking the newborn, disclosure of HIV test results to the mother, facility compliance reviews, and educational activities related to the HIV testing.
c. The provisions of this section shall not apply to a newborn whose parents object to the test as being in conflict with their religious tenets and practices. The parents shall provide the health care facility with a written statement of the objection, and the statement shall be included in the newborn's medical record.
d. As used in this section, "birthing facility" means an inpatient or ambulatory health care facility licensed by the Department of Health that provides birthing and newborn care services.
e. The Commissioner of Health shall adopt rules and regulations, pursuant to the "Administrative Procedure Act," P.L.1968, c.410 (C.52:14B-1 et seq.), necessary to carry out the purposes of this section.
L.2007, c.218, s.4; amended 2012, c.17, s.118.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-111.3 - Findings, declarations relative to newborn screening for congenital heart defects.

26:2-111.3 Findings, declarations relative to newborn screening for congenital heart defects.
1. The Legislature finds and declares that:
a. Congenital heart defects (CHDs) are structural abnormalities of the heart that are present at birth; CHDs range in severity from simple problems such as holes between chambers of the heart, to severe malformations, such as the complete absence of one or more chambers or valves; some critical CHDs can cause severe and life-threatening symptoms which require intervention within the first days of life;
b. According to the United States Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children, congenital heart disease affects approximately seven to nine of every 1,000 live births in the United States and Europe; the federal Centers for Disease Control and Prevention states that CHD is the leading cause of infant death due to birth defects;
c. Current methods for detecting CHDs generally include prenatal ultrasound screening and repeated clinical examinations; while prenatal ultrasound screenings can detect some major congenital heart defects, these screenings, alone, identify less than half of all CHD cases, and critical CHD cases are often missed during routine clinical exams performed prior to a newborn's discharge from a birthing facility;
d. Pulse oximetry is a non-invasive test that estimates the percentage of hemoglobin in blood that is saturated with oxygen; when performed on a newborn a minimum of 24 hours after birth, pulse oximetry screening is often more effective at detecting critical, life-threatening CHDs which otherwise go undetected by current screening methods; newborns with abnormal pulse oximetry results require immediate confirmatory testing and intervention; and
e. Many newborn lives could potentially be saved by earlier detection and treatment of CHDs if birthing facilities in the State were required to perform this simple, non-invasive newborn screening in conjunction with current CHD screening methods.
L.2011, c.74, s.1.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-111.4 - Birthing facilities required to perform pulse oximetry screening; rules, regulations.

26:2-111.4 Birthing facilities required to perform pulse oximetry screening; rules, regulations.
2. a. The Commissioner of Health shall require each birthing facility licensed by the Department of Health to perform a pulse oximetry screening, a minimum of 24 hours after birth, on every newborn in its care.
b. As used in this section, "birthing facility" means an inpatient or ambulatory health care facility licensed by the Department of Health that provides birthing and newborn care services.
c. The commissioner shall adopt rules and regulations, pursuant to the "Administrative Procedure Act," P.L.1968, c.410 (C.52:14B-1 et seq.), necessary to carry out the purposes of this act.
L.2011, c.74, s.2; amended 2012, c.17, s.119.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-111.5 - Testing of newborns for certain lysomal storage disorders required.

26:2-111.5 Testing of newborns for certain lysomal storage disorders required.
1. a. All infants born in this State shall be tested for the lysosomal storage disorders known as Krabbe, Pompe, Gaucher, Fabry, and Niemann-Pick diseases within six months following the occurrence of all of the following:
(1) the registration with the federal Food and Drug Administration of the necessary reagents;
(2) the availability of the necessary reagents from the federal Centers for Disease Control and Prevention;
(3) the availability of quality assurance testing methodology for these processes; and
(4) the acquisition by the Department of Health of the equipment necessary to implement the expanded screening tests.
b. The Department of Health may charge a reasonable fee for the tests performed pursuant to this section. The amount of the fee and the procedures for collecting the fee shall be determined by the Commissioner of Health.
L.2011, c.175, s.1; amended 2012, c.17, s.120.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-111.6 - Testing of infants for adrenoleukodystrophy.

26:2-111.6 Testing of infants for adrenoleukodystrophy.
1. a. All infants born in this State shall be tested for adrenoleukodystrophy (ALD) beginning six months following the occurrence of all of the following:
(1) the development of a reliable test or series of tests for screening newborns for ALD using dried blood spots and quality assurance testing methodology for ALD testing;
(2) the availability of quality assurance materials for the ALD test from the federal Centers for Disease Control and Prevention;
(3) the inclusion of newborn screening for ALD in the Recommended Uniform Screening Panel of the United States Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children, after the committee's evidence review of newborn screening for ALD;
(4) the review by the Department of Health of the proposed test; and
(5) the acquisition of equipment necessary to implement the expanded screening tests by the State's Newborn Screening Laboratory.
b. The Department of Health may charge a reasonable fee and any reasonable increase in this fee as necessary, for the test performed pursuant to this section. The amount of the fee and the procedures for collecting the fee shall be determined by the Commissioner of Health.
L.2013, c.90, s.1.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-111.7 - "Let Them Be Little Act," screening of newborns for MPSI and MPSII provided.

26:2-111.7 "Let Them Be Little Act," screening of newborns for MPSI and MPSII provided.
1. a. All infants born in this State shall be tested for mucopolysaccharidosis I (MPS I), also known as Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome, beginning six months following the occurrence of all of the following:
(1) the development of a reliable test or series of tests for screening newborns for MPS I using dried blood spots and quality assurance testing methodology for Hunter syndrome testing;
(2) the availability of quality assurance materials for the MPS I test from the federal Centers for Disease Control and Prevention;
(3) the inclusion of newborn screening for MPS I in the Recommended Uniform Screening Panel of the United States Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children, after the committee's evidence review of newborn screening for MPS I;
(4) the review by the Department of Health of the proposed test; and
(5) the acquisition of equipment necessary to implement the expanded screening tests by the State's Newborn Screening Laboratory.
b. All infants born in this State shall be tested for mucopolysaccharidosis II (MPS II), also called Hunter syndrome, beginning six months following the occurrence of all of the following:
(1) the development of a reliable test or series of tests for screening newborns for MPS II using dried blood spots and quality assurance testing methodology for Hunter syndrome testing;
(2) the availability of quality assurance materials for the MPS II test from the federal Centers for Disease Control and Prevention;
(3) the inclusion of newborn screening for MPS II in the Recommended Uniform Screening Panel of the United States Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children, after the committee's evidence review of newborn screening for MPS II;
(4) the review by the Department of Health of the proposed test; and
(5) the acquisition of equipment necessary to implement the expanded screening tests by the State's Newborn Screening Laboratory.
c. The Department of Health may charge a reasonable fee and any reasonable increase in this fee as necessary, for the tests performed pursuant to this section. The amount of the fee and the procedures for collecting the fee shall be determined by the Commissioner of Health.
L.2014, c.44, s.1.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-111.8 - Screening of newborn infants for spinal muscular atrophy.

26:2-111.8 Screening of newborn infants for spinal muscular atrophy.
1. a. Each infant born in this State shall be tested for the genetic mutations associated with spinal muscular atrophy.
b. The Commissioner of Health shall develop a comprehensive program of follow-up services and procedures in the event a newborn tests positive for one or more genetic markers associated with spinal muscular atrophy, which services and procedures shall include, at a minimum:
(1) genetic counseling for the parents of the newborn concerning the risk that one or both parents is a carrier of the genetic mutation associated with spinal muscular atrophy, and the risk that other children born to the parents may carry the mutation, pass it on to their own offspring, or may be born with spinal muscular atrophy; and
(2) information concerning available treatment options for spinal muscular atrophy.
c. The Department of Health may charge a reasonable fee to administer tests performed pursuant to this section. The amount of the fee and the procedures for collecting the fee shall be determined by the Commissioner of Health.
d. The Commissioner of Health shall adopt rules and regulations, pursuant to the "Administrative Procedure Act," P.L.1968, c.410 (C.52:14B-1 et seq.), necessary to carry out the purposes of this section.
L.2019, c.390, s.1.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-111.9 - All infants tested, congenital cytomegalovirus; opting out of testing.

26:2-111.9 All infants tested, congenital cytomegalovirus; opting out of testing.
1. a. All infants born in this State shall be tested for congenital cytomegalovirus infection (cCMV), unless an infant's parent or legal guardian opts out of testing, beginning six months following the occurrence of all of the following:
(1) the development of a reliable test or series of tests for screening newborns for cCMV using dried blood spots and quality assurance testing methodology for cCMV testing;
(2) the availability of quality assurance materials for the cCMV test from the federal Centers for Disease Control and Prevention;
(3) the inclusion of newborn screening for cCMV in the Recommended Uniform Screening Panel of the United States Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children, after the committee's evidence review of newborn screening for cCMV;
(4) the recommendation by the Newborn Screening Advisory Review Committee established pursuant to section 2 of P.L.2019, c.296 (C.26:2-110a) that the test be included in the State Newborn Screening Program;
(5) the Commissioner of Health's approval to include the test in the State's Newborn Screening Program, which approval shall be based on the recommendations of the Newborn Screening Advisory Review Committee; and
(6) the acquisition of equipment necessary to implement the expanded screening tests by the State's Newborn Screening Laboratory.
b. The Department of Health may charge a reasonable fee for the test performed pursuant to this section in such amount as shall be determined by the Commissioner of Health, and may periodically increase the fee by any reasonable amount as the commissioner determines to be necessary. The procedures for collecting the fee shall be determined by the commissioner.
L.2021, c.413, s.1.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-111.10 - Public awareness campaign established.

26:2-111.10 Public awareness campaign established.
2. a. The Commissioner of Health shall establish a public awareness campaign to educate pregnant persons about cytomegalovirus (CMV) and cCMV and the value of early detection of, interventions for, and possible treatments for, CMV and cCMV.
b. The commissioner, in establishing the public awareness campaign, shall develop outreach efforts and provide information and educational materials to pregnant persons on CMV and cCMV including, but not limited to:
(1) the cause and nature of CMV and cCMV;
(2) diagnostic procedures and appropriate indications for their use;
(3) lifestyle issues relating to how a pregnant person can pass cCMV to a developing fetus; and
(4) the availability of CMV and cCMV diagnostic and treatment services in the community.
c. The commissioner shall prepare, and make available on the Department of Health's Internet website, in English and Spanish, and in a manner that is easily understandable by a pregnant person, information about the symptoms and treatment of CMV and cCMV and any other information that the commissioner deems to be necessary. This information may be revised by the department whenever new information about CMV and cCMV becomes available.
L.2021, c.413, s.2.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-112 - Agreements with federal government and public health agencies of other states

26:2-112. Agreements with federal government and public health agencies of other states
The commissioner is authorized to enter into agreements with the Federal Government and public health agencies in other states to achieve greater effectiveness or efficiency in carrying out the provisions of this act.
L.1981, c. 357, s. 4.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-113 - Legislative findings and declarations

26:2-113. Legislative findings and declarations
The Legislature finds that the effective identification, diagnosis, care and treatment of persons who have been exposed to diethylstilbestrol, commonly referred to as DES, is of paramount public importance; that DES, a synthetic estrogen-type hormone, was extensively administered between 1940 and 1970 to pregnant women threatened with miscarriage; that, subsequently, a causal relationship was found between DES and an unusual type of cervical and vaginal cancer in the daughters of persons who took the drug during pregnancy; that use of DES during pregnancy has been discontinued as a result of these findings, but that as many as 75,000 persons in New Jersey may have been exposed to the drug during its period of usage.
The Legislature further finds that the magnitude of this problem may only be realized in the next few years as the daughters of women exposed to the drug reach reproductive age, the time when such abnormalities become apparent; that the situation is compounded by the relative newness of the studies associating DES with cancer and the uncertainty over the implications of recent research; and that many physicians are not yet familiar with detection and treatment techniques because the problem has been relatively recently identified.
Therefore, the Legislature declares that it is imperative that programs be established to identify and diagnose persons who have been exposed to the drug diethylstilbestrol, to refer them to sources of care and treatment, and to provide an education program for physicians and other health care professionals so that exposed persons may benefit from the best possible diagnostic procedures and treatment.
L.1981, c. 288, s. 1, eff. Sept. 23, 1981.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-114 - Definitions

26:2-114. Definitions
As used in this act:
a. "Primary screening" means the initial evaluation of a person through history, physical examination and routine tests to determine the possible existence of physical changes due to diethylstilbestrol exposure; and
b. "Secondary screening" means a follow-up evaluation with specialized diagnostic measures of a person identified in a primary screening as having a high probability of being diethylstilbestrol exposed, in order to confirm the existence of changes attributed to that exposure.
L.1981, c. 288, s. 2, eff. Sept. 23, 1981.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-115 - Duties of commissioner; programs of education; secondary screening programs

26:2-115. Duties of commissioner; programs of education; secondary screening programs
The Commissioner of the Department of Health shall establish:
a. A program to educate the public and health care professionals involved in primary screening about the potential hazards and afflictions which may be related to exposure to diethylstilbestrol and the symptoms and prevention of associated malignancies. The program shall include a public information campaign on diethylstilbestrol to encourage persons exposed to the drug to seek medical care for the prevention or treatment of any malignant condition.
b. Secondary screening programs for diethylstilbestrol exposed persons through contract with licensed health care facilities. In contracting for the secondary screening programs, consideration shall be given to the location of the facility in relation to the concentration of population within the State and the capacity of the facility to properly conduct a secondary screening program. Each contract for a secondary screening program shall be upon such terms and conditions as the Commissioner of Health determines; but each facility shall charge each person receiving services a fee as determined by the commissioner. Where provided, all third party payors shall be accepted and utilized in securing payment for services.
c. Continuing education programs for health care professionals involved in the diagnosis and treatment of diethylstilbestrol exposed persons.
L.1981, c. 288, s. 3, eff. Sept. 23, 1981.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-116 - Registry

26:2-116. Registry
The Commissioner of the Department of Health shall maintain a registry of women who took diethylstilbestrol during pregnancy and their offspring who were exposed to diethylstilbestrol prenatally for the purpose of follow-up care and treatment of long-term problems associated with diethylstilbestrol exposure. Enrollment in the registry shall be upon a voluntary basis.
L.1981, c. 288, s. 4, eff. Sept. 23, 1981.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-117 - Annual report

26:2-117. Annual report
The Department of Health shall make an annual report to the Legislature, through the President of the Senate, Speaker of the General Assembly and Chairmen of the Senate and Assembly Institutions, Health and Welfare Committees of its findings and recommendations concerning the effectiveness, impact and benefits derived from the programs created herein, and any recommendations for legislative changes deemed necessary.
L.1981, c. 288, s. 5, eff. Sept. 23, 1981.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-119 - Legislative findings

26:2-119. Legislative findings
The Legislature finds that every year there are a substantial number of accidental poisonings especially among young children and that the possibility of serious injury or death which results from the ingestion of poisonous substances could be dramatically reduced by the development of a poison control and drug information program.
L.1982, c. 177, s. 1, eff. Nov. 12, 1982.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-120 - Definitions

26:2-120. Definitions
As used in this act:
a. "Commissioner" means the Commissioner of the Department of Health;
b. "Program" means the poison control and drug information program established by the commissioner.
L.1982, c. 177, s. 2, eff. Nov. 12, 1982.
2023 New Jersey Revised Statutes › Title 26 - Health and Vital Statistics › Section 26:2-121 - Poison control and drug information program; establishment; hours of service

26:2-121. Poison control and drug information program; establishment; hours of service
The commissioner shall establish a Statewide program of poison control and drug information. Program services shall be available on a 24 hour basis to the residents of every county.
L.1982, c. 177, s. 3, eff. Nov. 12, 1982.